SIC
GNOM icon

Salem Investment Counselors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Salem Investment Counselors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-388
Closed -$19K – 1064
2022
Q2 		$19K Hold
388
– – ﹤0.01% 664
2022
Q1 		$23K Hold
388
– – ﹤0.01% 628
2021
Q4 		$31K Buy
+388
New +$32.6K ﹤0.01% 635

Other funds holding GNOM

Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Salem Investment Counselors's GNOM Position: Q3 2022 in Review

Salem Investment Counselors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q3 2022, closing a stake of 388 shares — an estimated $19K sold.

Salem Investment Counselors first reported a position in GNOM in Q4 2021 and held it in 3 quarters. The position peaked at $31K in Q4 2021. 59 funds tracked by Wall St. Rank hold GNOM as of Q3 2022.

  • Salem Investment Counselors reported no remaining Global X Genomics & Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
  • Salem Investment Counselors sold 388 Global X Genomics & Biotechnology ETF shares in Q3 2022, an estimated $19K.
  • Salem Investment Counselors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 3 quarters.
  • Salem Investment Counselors's Global X Genomics & Biotechnology ETF position peaked at $31K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2022.

Based on Salem Investment Counselors's 13F filing for Q3 2022, filed 9 Nov 2022.